8-K filing — MAXCYTE, INC. (MXCT)
Filed: 2026-08-12 AccNo: 0001104659-26-094886 Size: 6 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
MaxCyte Launches CHANGE-seq-BE And ONE-seq-BE Off-Target Nomination Assays
MaxCyte, Inc. (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
MaxCyte Affirms FY2026 Sales Guidance of $30.000M-$32.000M vs $31.082M Est
MaxCyte (NASDAQ:MXCT) affirms FY2026 sales outlook from $30.000 million-$32.000 million to $30.000 million-$32.000 million vs $31.082 million estimate.
MaxCyte Q2 EPS $(0.08) Beats $(0.09) Estimate, Sales $7.271M Beat $6.475M Estimate
MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 33.33 percent increase over losses of $(0.12) per share from the same